{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enbrel&page=6", "query": { "intervention": "Enbrel", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 167, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enbrel&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enbrel&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T22:32:20.158Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01009879", "title": "Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-11", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-10-19T22:32:20.158Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01009879" }, { "nct_id": "NCT01690299", "title": "Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Psoriatic Arthritis" ], "interventions": [ { "name": "Apremilast", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Placebo tablet", "type": "DRUG" }, { "name": "Placebo injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2012-10-01", "completion_date": "2016-04-04", "has_results": true, "last_update_posted_date": "2022-03-15", "last_synced_at": "2026-10-19T22:32:20.158Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01690299" }, { "nct_id": "NCT05281614", "title": "Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" }, { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Benaroya Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 20, "start_date": "2022-09-21", "completion_date": "2024-01-10", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-10-19T22:32:20.158Z", "location_count": 2, "location_summary": "La Jolla, California • Seattle, Washington", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05281614" }, { "nct_id": "NCT00585650", "title": "Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Etanercept", "type": "BIOLOGICAL" }, { "name": "Placebo injections", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "2007-05", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2023-08-18", "last_synced_at": "2026-10-19T22:32:20.158Z", "location_count": 3, "location_summary": "Irvine, California • Winston-Salem, North Carolina • Seattle, Washington", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585650" }, { "nct_id": "NCT06654882", "title": "Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polyarticular Course Juvenile Idiopathic Arthritis (JIA)" ], "interventions": [ { "name": "TNFi (Tumor Necrosis Factor inhibitor) medication", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 400, "start_date": "2026-01-09", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-19T22:32:20.158Z", "location_count": 4, "location_summary": "San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06654882" }, { "nct_id": "NCT02374021", "title": "Treatments Against RA and Effect on FDG-PET/CT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 159, "start_date": "2016-07", "completion_date": "2021-05", "has_results": true, "last_update_posted_date": "2022-10-26", "last_synced_at": "2026-10-19T22:32:20.158Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02374021" }, { "nct_id": "NCT00201838", "title": "Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Neoplasms", "Adenocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2001-07", "completion_date": "2007-05", "has_results": true, "last_update_posted_date": "2017-11-30", "last_synced_at": "2026-10-19T22:32:20.158Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00201838" }, { "nct_id": "NCT00841789", "title": "A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucocutaneous Lymph Node Syndrome", "Kawasaki Disease" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Portman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "20 Years", "sex": "ALL", "summary": "2 Months to 20 Years" }, "enrollment_count": 205, "start_date": "2009-03", "completion_date": "2018-08-30", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-10-19T22:32:20.158Z", "location_count": 7, "location_summary": "New Hyde Park, New York • New York, New York • The Bronx, New York + 4 more", "locations": [ { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00841789" }, { "nct_id": "NCT01597245", "title": "A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "80 mg ixekizumab Dosing Regimen", "type": "DRUG" }, { "name": "50 mg etanercept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1224, "start_date": "2012-05-18", "completion_date": "2019-06-18", "has_results": true, "last_update_posted_date": "2020-06-26", "last_synced_at": "2026-10-19T22:32:20.158Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01597245" }, { "nct_id": "NCT00001901", "title": "Etanercept to Treat Wegener's Granulomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vasculitis", "Wegener's Granulomatosis" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 60, "start_date": "1999-02", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-19T22:32:20.158Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001901" } ] }